Valuation: Ovid Therapeutics Inc.

Market Cap 51Cr 45Cr 41Cr 38Cr 72Cr 4.88TCr 74Cr 496.01Cr 192.72Cr 2.39TCr 191.34Cr 187.15Cr 8.29TCr P/E 2026 *
-5.65x
P/E 2027 * -5.12x
Enterprise Value 51Cr 45Cr 41Cr 38Cr 72Cr 4.88TCr 74Cr 496.01Cr 192.72Cr 2.39TCr 191.34Cr 187.15Cr 8.29TCr EV / Sales 2026 *
4,740x
EV / Sales 2027 * 3,057x
Free-Float
93.01%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Ovid Therapeutics Inc.

1 day-1.09%
1 week+1.87%
Current month+1.49%
1 month+15.68%
3 months+5.00%
6 months+57.80%
Current year+67.48%
1 week 2.49
Extreme 2.49
2.82
1 month 2.16
Extreme 2.162
2.84
Current year 1.36
Extreme 1.36
3.1
1 year 0.36
Extreme 0.36
3.1
3 years 0.24
Extreme 0.2425
4.14
5 years 0.24
Extreme 0.2425
4.2
10 years 0.24
Extreme 0.2425
15.93
Manager TitleAgeSince
Chief Executive Officer 45 01/01/2026
Director of Finance/CFO 57 02/06/2021
Chief Tech/Sci/R&D Officer 60 02/12/2025
Director TitleAgeSince
Chairman 72 01/04/2014
Director/Board Member 73 30/09/2015
Director/Board Member 81 23/11/2015
Date Insider Type Main position Quantity % Market Cap.
15/06Free

Director

1,30,000 0.0697%
07/04Free

Director

17,578 0.0133%
07/04Free

Director

8,789 0.0067%
Change 5-day change 1-year change 3-year change Capi.($)
-1.09%+1.87%+534.88%-19.71% 52Cr
-1.53%+0.78%+72.33%+129.70% 5.77TCr
-2.45%-7.83%+63.92%+83.15% 5.27TCr
+3.27%+8.91%+21.21%+486.76% 2.45TCr
-0.81%-0.42%-16.24%-12.47% 2.38TCr
-3.05%+3.06%+38.75%-5.66% 1.93TCr
-0.24%+5.11%+38.76%-26.41% 1.78TCr
+2.34%+12.50%+224.02%+380.99% 1.73TCr
-6.73%+9.90%+39.77% - 1.53TCr
-1.70%+3.98%+28.96%+190.57% 1.43TCr
Average -1.20%+5.15%+104.64%+134.10% 2.43TCr
Weighted average by Cap. -1.26%+3.12%+58.72%+141.30%

Financials

2026 *2027 *
Net sales 1L 94.29T 87.05T 80.44T 2L 1.03Cr 2L 10.46L 4L 50.37L 4L 4L 1.75Cr 2L 1L 1L 1L 2L 1.6Cr 2L 16.22L 6L 78.1L 6L 6L 2.71Cr
Net income -7.71Cr -6.76Cr -6.24Cr -5.77Cr -11Cr -738.45Cr -11Cr -75Cr -29Cr -361.37Cr -29Cr -28Cr -1.25TCr -8.98Cr -7.88Cr -7.27Cr -6.72Cr -13Cr -860.24Cr -13Cr -87Cr -34Cr -420.97Cr -34Cr -33Cr -1.46TCr
Net Debt - -
Logo Ovid Therapeutics Inc.
Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small-molecule medicines for brain conditions with significant unmet need. It is advancing a pipeline of novel, targeted small-molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of multiple neurological and neuropsychiatric disorders. It develops OV329, which is a GABA-aminotransferase inhibitor, as a potential therapy for treatment-resistant seizures and other undisclosed indications; OV350, OV4071 and others within a library of compounds that directly activate the KCC2 transporter, for multiple CNS disorders. It also maintains the KCC2 library, which is a portfolio of potential first-in-class direct activators of potassium chloride cotransporter2. Both OV350 and OV4071 are intended for the potential treatment of psychosis associated with neuronal-synuclein diseases (NSD), which include Parkinson’s disease and Lewy body dementia (LBD).
Employees
23
Date Price Change Volume
08/26/08 $2.730 -1.09% 30,27,302
07/26/07 $2.760 +5.75% 33,12,954
06/26/06 $2.610 -2.97% 11,55,658
02/26/02 $2.690 +0.37% 18,87,178
01/26/01 $2.680 -0.37% 14,13,462
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
2.730USD
Average target price
5.471USD
Spread / Average Target
+100.41%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OVID Stock